Culture Biosciences is a San Francisco-based company offering an integrated bioprocess development platform that combines automated laboratory hardware with cloud-native software. Its flagship Stratyx 250 system delivers scalable, digitally connected bioprocess capacity for biologics, cell therapy, and other advanced workflows. The accompanying Console software centralizes experimental data, making it accessible and contextualized for R&D teams across locations. The company is augmenting this platform with AI-driven capabilities such as predictive modeling, advanced data integration, and automated analysis tools aimed at shortening development cycles and sharpening process decisions. Culture Biosciences enables customers to run, monitor, and optimize experiments remotely, effectively moving biomanufacturing into the cloud. Proceeds from its latest funding will help roll out the Stratyx 250 commercially while expanding AI features within the Console platform. The article did not provide specific revenue, customer, or usage metrics.

Total raised

$101M

Funding rounds

4

Latest round

Series B

Latest activity

Oct 2021